ScoreWhy is Medicamen Biotech Ltd ?
1
Poor long term growth as Operating profit has grown by an annual rate -11.09% of over the last 5 years
2
With ROE of 3.9, it has a Expensive valuation with a 1.9 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -35.03%, its profits have risen by 45.6% ; the PEG ratio of the company is 1.4
3
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -35.03% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Medicamen Biotec for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Medicamen Biotec
-34.25%
-0.75
45.88%
Sensex
4.83%
0.41
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
7.04%
EBIT Growth (5y)
-11.09%
EBIT to Interest (avg)
6.99
Debt to EBITDA (avg)
1.40
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
0.67
Tax Ratio
23.99%
Dividend Payout Ratio
11.63%
Pledged Shares
0
Institutional Holding
0.70%
ROCE (avg)
7.68%
ROE (avg)
6.41%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
48
Industry P/E
34
Price to Book Value
1.85
EV to EBIT
59.49
EV to EBITDA
34.03
EV to Capital Employed
1.87
EV to Sales
3.07
PEG Ratio
1.31
Dividend Yield
0.27%
ROCE (Latest)
3.14%
ROE (Latest)
3.88%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
PAT(Latest six months)
At Rs 4.82 cr has Grown at 71.53%
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 43.68 cr
NET SALES(Q)
Highest at Rs 47.17 cr
-4What is not working for the Company
ROCE(HY)
Lowest at 4.69%
DEBTORS TURNOVER RATIO(HY)
Lowest at 2.13 times
Loading Valuation Snapshot...
Here's what is working for Medicamen Biotec
Profit After Tax (PAT) - Quarterly
At Rs 2.67 cr has Grown at 82.9%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 47.17 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 43.68 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Medicamen Biotec
Debtors Turnover Ratio- Half Yearly
Lowest at 2.13 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
